載入中
NASDAQHealthcareMedical - Pharmaceuticals
最新資料
US$7.78
−US$0.52 · -6.27%
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
收盤時
US$7.78
−US$0.52 · -6.27%
盤後
US$7.78
US$0.00 · 0.00%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
日內區間
目前US$7.78
52週區間
目前US$7.78
盤中時間採用ET。市場資料可能有所延遲。
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
日內區間
目前US$7.78
52週區間
目前US$7.78
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6202 USD | — | — | — | — |
| 銷貨成本 | 6318 USD | — | — | — | — |
| 毛利 | −116 USD | — | — | — | — |
| 研究與開發 | 92.39萬 USD | 14.44萬 USD | 7.21萬 USD | — | — |
| 銷售、一般及管理費用 | 1842.73萬 USD | 106.65萬 USD | 134萬 USD | 97.63萬 USD | 2.78萬 USD |
| 營業費用 | 1935.12萬 USD | 121.09萬 USD | 134萬 USD | 97.63萬 USD | 2.55萬 USD |
| 利息收入 | — | 54.87萬 USD | 581.3萬 USD | 431.66萬 USD | — |
| 利息支出 | 853.13萬 USD | 9.8萬 USD | 8966 USD | — | — |
| 折舊和攤銷 | 801.94萬 USD | — | 134.02萬 USD | — | 2.78萬 USD |
| 營業利益 | −1935.13萬 USD | −121.09萬 USD | −134萬 USD | −97.63萬 USD | −2.55萬 USD |
| 淨利 | −2448.08萬 USD | −130.99萬 USD | 446.4萬 USD | 334.02萬 USD | −2.55萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年5月11日 | 1:30 | — | — |
股票分割 | 2026年1月16日 | 1:40 | — | — |
已生效 2026年5月11日
1:30
已生效 2026年1月16日
1:40
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
